Lung Biopsy Systems Market Outlook:
Lung Biopsy Systems Market size was over USD 5.03 billion in 2025 and is projected to reach USD 20.89 billion by 2035, growing at around 15.3% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of lung biopsy systems is evaluated at USD 5.72 billion.
The reason behind the growth is impelled by a higher prevalence of lung cancer across the globe. As a result, there is a greater need for timely diagnosis which necessitates the use of a lung biopsy system. By extracting samples of lung tissue that may be utilized for molecular testing, a lung biopsy is a generally acknowledged method for identifying pulmonary illnesses. A report published by World Health Organization (WHO) stated that in 2020, around 10 million people died due to lung cancer which was summed up to be 1 in 6 deaths worldwide.
The growing inclination toward minimally invasive surgeries is believed to fuel lung biopsy systems market growth. Minimally invasive surgeries come under the ongoing advancement of the medtech industry and it is performed by delivering less damage to the body with the assistance of enhanced medical imaging equipment services.
Moreover, the use of a robotic-assisted system in minimally invasive lung biopsy enables medical professionals performing the procedure to access all 18 lung regions, enabling the best lung navigation and producing more precise biopsies. This type of treatment is safe, effective, and minimally invasive, which can reduce discomfort, recovery time, and infection risk.
